DB-OTO
DB-OTO-001
Phase 2 gene_therapy active
Quick answer
DB-OTO for Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) is a Phase 2 program (gene_therapy) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Regeneron UK Limited
- Indication
- Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
- Phase
- Phase 2
- Modality
- gene_therapy
- Status
- active